Lyndsey M. Muehling

Lyndsey M. Muehling

Auto-generated profile, based on publicly available information

Lyndsey M. Muehling

Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JWJulia A. Wisniewski
Julia A. Wisniewski
LMLyndsey M. Muehling
Lyndsey M. Muehling
JEJacob ECCLES
Jacob ECCLES
BCBrian Capaldo
Brian Capaldo
RARachana Agrawal
Rachana Agrawal
JWJudith A. Woodfolk
Judith A. Woodfolk

4 September 2024 in Nature
Verified
Journal Article
Closed access
PDF file
HNHarish Narasimhan
Harish Narasimhan
ICIn Su Cheon
In Su Cheon
WQWei Qian
Wei Qian
SHSheng’en Shawn Hu
Sheng’en Shawn Hu
TPTanyalak Parimon
Tanyalak Parimon
JSJie Sun
Jie Sun

1 December 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LMLyndsey M. Muehling
Lyndsey M. Muehling
MLMonica G. Lawrence
Monica G. Lawrence
JWJudith A. Woodfolk
Judith A. Woodfolk

26 April 2017 in Beneficial Microbes
Verified
Journal Article
Open access
RTR.B. Turner
R.B. Turner
JWJ.A. Woodfolk
J.A. Woodfolk
LBL. Borish
L. Borish
JSJ.W. Steinke
J.W. Steinke
JPJ.T. Patrie
J.T. Patrie
MLM.J. Lehtinen
M.J. Lehtinen
Ingestion of probiotics appears to have modest effects on the incidence of viral respiratory infection. The mechanism of these effects is not clear; however, there is evidence from animal models that the probiotic may have an effect on innate immune responses to pathogens. The purpose of this randomised, placebo-controlled study was to determine the effect of administration of Bifidobacterium animalis subspecies lactis Bl-04 on innate and adaptive host responses to experimental rhinovirus challenge. The effect on the response of chemokine (C-X-C motif) ligand 8 (CXCL8) to rhinovirus infection was defined as the primary endpoint for the study. 152 seronegative volunteers who had been supplemented for 28 days, 73 with probiotic and 79 with placebo, were challenged with RV-A39. Supplement or placebo administration was then continued for five days during collection of specimens for assessment of host response, infection, and symptoms. 58 probiotic and 57 placebo-supplemented volunteers met protocol-defined criteria for analysis. Probiotic resulted in higher nasal lavage CXCL8 on day 0 prior to virus challenge (90 vs 58 pg/ml, respectively, P=0.04, ANCOVA). The CXCL8 response to rhinovirus infection in nasal lavage was significantly reduced in the probiotic treated group (P=0.03, ANCOVA). Probiotic was also associated with a reduction in nasal lavage virus titre and the proportion of subjects shedding virus in nasal secretions (76% in the probiotic group, 91% in the placebo group, P=0.04, Fisher Exact test). The administration of probiotic did not influence lower respiratory inflammation (assessed by exhaled nitric oxide), subjective symptom scores, or infection rate. This study demonstrates that ingestion of Bl-04 may have an effect on the baseline state of innate immunity in the nose and on the subsequent response of the human host to rhinovirus infection. Clinicaltrials.gov registry number: NCT01669603.

5 August 2021 in eLife
Verified
Journal Article
Open access
SBSierra M Barone
Sierra M Barone
APAlberta Gerarda Antonia Paul
Alberta Gerarda Antonia Paul
LMLyndsey M Muehling
Lyndsey M Muehling
JLJoanne A Lannigan
Joanne A Lannigan
WKWilliam W. Kwok
William W. Kwok
JIJonathan M Irish
Jonathan M Irish
For an emerging disease like COVID-19, systems immunology tools may quickly identify and quantitatively characterize cells associated with disease progression or clinical response. With repeated sampling, immune monitoring creates a real-time portrait of the cells reacting to a novel virus before disease-specific knowledge and tools are established. However, single cell analysis tools can struggle to reveal rare cells that are under 0.1% of the population. Here, the machine learning workflow Tracking Responders EXpanding (T-REX) was created to identify changes in both rare and common cells across human immune monitoring settings. T-REX identified cells with highly similar phenotypes that localized to hotspots of significant change during rhinovirus and SARS-CoV-2 infections. Specialized MHCII tetramer reagents that mark rhinovirus-specific CD4+ cells were left out during analysis and then used to test whether T-REX identified biologically significant cells. T-REX identified rhinovirus-specific CD4+ T cells based on phenotypically homogeneous cells expanding by ≥95% following infection. T-REX successfully identified hotspots of virus-specific T cells by comparing infection (day 7) to either pre-infection (day 0) or post-infection (day 28) samples. Plotting the direction and degree of change for each individual donor provided a useful summary view and revealed patterns of immune system behavior across immune monitoring settings. For example, the magnitude and direction of change in some COVID-19 patients was comparable to blast crisis acute myeloid leukemia patients undergoing a complete response to chemotherapy. Other COVID-19 patients instead displayed an immune trajectory like that seen in rhinovirus infection or checkpoint inhibitor therapy for melanoma. The T-REX algorithm thus rapidly identifies and characterizes mechanistically significant cells and places emerging diseases into a systems immunology context for comparison to well-studied immune changes.

30 July 2022 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
NBNaomi Bryant
Naomi Bryant
LMLyndsey M. Muehling
Lyndsey M. Muehling